(2.3) Dosage Forms and Strengths Injection (3): o 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, 2.4 mg/0.75 mL, or 7.2 mg/0.75 mL (WEGOVY HD) in a single-dose pen o 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, or 2.4 mg/0.75 mL in a single-dose syringe o 9.6 mg/3 mL (3.2 mg/mL) solution in a single-patient-use pen (WEGOVY FlexTouch) that delivers four 2.4 mg/0.75 mL doses Tablets: 1.5 mg, 4 mg, 9 mg and 25 mg (3) Contraindications Warnings and Precautions Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, including WEGOVY
For instance, according to the latest International Diabetes Federation (IDF) Diabetes Atlas (2025), approximately 11.1% of adults aged 2079 yearsabout 1 in 9 peopleare living with diabetes globally, and more than 4 in 10 of those individuals remain undiagnosed
Watch for persistent fatigue unrelated to dose escalation, unexplained cold intolerance, muscle aches, slowed heart rate, or unexpected weight loss plateau despite adherence
Probiotics are more reliably effective for constipation, bloating, and diarrhea